Biotech Consolidation: Even News is No News
Executive Summary
The only thing more noteworthy about the recent biotech M&A is than its volume is the silence that surrounds it: from Wall Street, the press, and Big Pharma. The problem is the consolidations themselves: largely intra-biotech affairs. Unless Big Pharma gets involved--and they've shown no interest in doing so--investors aren't going to get paid in what they want most out of an acquisition: liquid currency.